Ebvallo 2.8 x 107 – 7.3 x 107 cells/mL dispersion for injection – patient leaflet, side effects, dosage

1. What Ebvallo is and what it is used for

Ebvallo contains the active substance tabelecleucel.

Tabelecleucel is an allogeneic T-cell immunotherapeutic. It is called an allogeneic immunotherapeutic because the blood cells used to make this medicine come from human donors who are not related to the patient who is being treated. Ebvallo is made in a laboratory from T cells (a type of white blood cell) from a healthy donor who is immune to the Epstein-Barr virus. These cells have been individually selected to match with the patient receiving Ebvallo. Ebvallo is given as an injection into a vein.

Ebvallo is used to treat a rare kind of cancer called Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV⁺ PTLD) for adults and children 2 years of age and older. Some people experience this condition months or years after they have had a transplant. Patients will have received treatment with other medicines for this condition, such as monoclonal antibodies or chemotherapy, before they are given Ebvallo.

2. What you need to know before you are given Ebvallo

You must not be given Ebvallo

• if you are allergic to tabelecleucel or any of the other ingredients of this medicine (listed in section 6). If you think you may be allergic, ask your doctor for advice.

Warnings and precautions

Talk to your doctor or nurse before you are given Ebvallo if:

• you have had a solid organ transplant or bone marrow transplant, so your doctor can monitor you for signs and symptoms of transplant rejection.
• you are 65 years of age or older, so your doctor can monitor you for serious side effects. Ebvallo should be used with caution in elderly patients.

Talk to your doctor or nurse after you are given Ebvallo if:

• you have signs and symptoms of tumour flare reaction. Depending on the location of the tumour, Ebvallo can cause a side effect called tumour flare reaction. The tumour or enlarged lymph nodes may become suddenly painful or increase in size and could cause problems for organs next

  to the tumour. Tumour flare reaction generally occurs in the first few days after receiving Ebvallo. Your doctor will monitor you after the first few doses to see if your tumour or lymph node could get big enough to cause problems. Your doctor may give you other medicines to treat/prevent tumour flare reaction.

  • you have signs and symptoms of graft-versus-host disease (GvHD), such symptoms include skin rash, abnormal liver enzymes in the blood, yellowing of the skin, nausea, vomiting, diarrhoea and bloody stools.
  • you have signs and symptoms of a serious immune reaction called cytokine release syndrome (CRS), such as fever, chills, low blood pressure and shortness of breath.
  • you have signs and symptoms of a serious immune reaction called immune effector cell-associated neurotoxicity syndrome (ICANS), such as depressed level of consciousness, confusion, seizures and swelling of the brain.
  • you have signs and symptoms of infusion-related reactions, such as fever.

An ingredient of Ebvallo called dimethyl sulfoxide (DMSO) may cause an allergic reaction. Your doctor or nurse will monitor you for signs and symptoms of an allergic reaction. See section 2 “Ebvallo contains sodium and dimethyl sulfoxide (DMSO)”.

Ebvallo is tested for the presence of infectious microbes, but a small risk of infection remains. Your doctor or nurse will monitor you for signs and symptoms of infections and provide treatment as needed.

After treatment with Ebvallo, you must not donate blood, organs, tissues or cells.

Other medicines and Ebvallo

Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.

Before you are given Ebvallo, tell your doctor or nurse if you are taking medicines such as chemotherapy or corticosteroids. If you are taking chemotherapy, this medicine may affect how well Ebvallo works. If you are taking corticosteroids, your doctor will reduce the dose of corticosteroids.

Pregnancy, breast-feeding and fertility

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before you are given this medicine. This is because the effects of this medicine in pregnant or breast-feeding women are not known, and it may harm your unborn baby or your breast-fed child. Ebvallo is not recommended during pregnancy and in women who could become pregnant not using contraception.

• If you are pregnant or think you may be pregnant after you have started treatment with Ebvallo, talk to your doctor immediately.
• Discuss the need for contraception with your doctor.
• Tell your doctor if you are breast-feeding or plan to do so. Your doctor will then help you decide whether to stop breast-feeding or whether to stop taking Ebvallo, considering the benefit of breast-feeding the baby and the benefit of Ebvallo to the mother.

Driving and using machines

Ebvallo has minor influence on the ability to drive or use machines. If you experience changes in your thinking or level of alertness after being treated with this medicine, do not drive or operate machines and tell your doctor immediately.

Ebvallo contains sodium and dimethyl sulfoxide (DMSO)

This medicine contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially ‘sodium-free’.

This medicine contains 100 mg DMSO per mL. See Section 2 “Warnings and precautions”.

3. How Ebvallo is given

Ebvallo will always be given to you by a doctor or nurse in a treatment centre.

Your doctor or nurse will give you Ebvallo by injection into a vein. This usually takes 5 to 10 minutes for each injection.

Each cycle of treatment consists of 35 days. You will be given 1 injection per week for 3 weeks, followed by approximately 2 weeks of observation to see if you will need more than one cycle. Your doctor will decide the number of cycles you will receive based on how your disease responds to Ebvallo.

Before you are given Ebvallo

Your doctor or nurse will monitor your vital signs prior to each injection.

After you are given Ebvallo

Your doctor or nurse will monitor your vital signs, including blood pressure, for about 1 hour following the injection.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Serious side effects

Tell your doctor immediately if you get any of the following side effects after receiving Ebvallo:

• Tumour flare reaction with symptoms such as shortness of breath, changes in your thinking or level of alertness, pain at the tumour site, tender swollen lymph nodes at the tumour site, low grade fever.
• Graft-versus-host disease (GvHD) with symptoms such as skin rash, abnormal liver enzymes in the blood, yellowing of the skin, nausea, vomiting, diarrhoea and bloody stools.
• Serious immune reaction called Cytokine release syndrome (CRS), that may cause fever, chills, low blood pressure and shortness of breath.

Other possible side effects

Very common (may affect more than 1 in 10 people)

• Fever
• Diarrhoea
• Tiredness
• Feeling sick (nausea)
• Low levels of red blood cells (anaemia)
• Decreased appetite
• Decreased levels of sodium in the blood
• Abdominal pain or discomfort
• Decreased number of white blood cells (including neutrophils)
• Increased liver enzymes in the blood
• Constipation
• Increased levels of the enzyme alkaline phosphatase in the blood
• Decreased oxygen levels
• Dehydration
• Low blood pressure
• Stuffy nose
• Skin rash which may be red, bumpy or pus-filled

Common (may affect up to 1 in 10 people)

• Dizziness
• Headache
• Decreased levels of magnesium, potassium or calcium in the blood
• Itching
• Chills
• Decreased number of white blood cells (lymphocytes)
• Decreased number of white blood cells (neutrophils) with fever

• Muscular weakness

  • Joint pain, swelling and stiffness
  • Increased levels of creatinine in the blood
  • Wheezing
  • Confusion and disorientation
  • Back pain
  • Muscle pain
  • Nose and throat infection
  • Chest pain
  • Increased levels of lactate dehydrogenase in the blood
  • Inflammation of the colon
  • Pain
  • Decreased number of platelets in the blood
  • Bloating
  • Delirium
  • Depressed level of consciousness
  • Hot flush
  • Inflammation of the lungs
  • Sleepiness
  • Fast heartbeat
  • Tumour pain
  • Decreased levels of fibrinogen in the blood (a protein involved in blood clotting)
  • Flatulence
  • Swelling
  • Skin ulcer
  • Blue skin colour due to low oxygen levels
  • Difficult or painful bowel movement
  • General physical health deterioration
  • Numbness, tingling or burning sensation in hands or feet
  • Bleeding in the lungs
  • Skin discolouration
  • Skin infection
  • Destruction of soft tissue
  • Persistent cough

Reporting of side effects

If you get any side effects, talk to your doctor or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. How to store Ebvallo

Your doctor, pharmacist or nurse is responsible for storing this medicine and disposing of any unused product correctly. The following information is intended for healthcare professionals.

Do not use this medicine after the expiry date. The expiry date is provided on the Lot Information Sheet (LIS) and carton.

Store Ebvallo frozen in the vapour phase of liquid nitrogen at -150 °C or below until thawed for use.

The medicine should be thawed and diluted within 1 hour from the start of thaw. Administration must be completed within 3 hours from the start of thaw.

Store between 15 °C to 25 °C after thawing and dilution are complete. Protect product from light. Do not refreeze. Do not irradiate.

6. Contents of the pack and other information

What Ebvallo contains

• Ebvallo contains tabelecleucel at an approximate concentration of 2.8 x 10⁷ – 7.3 x 10⁷ cells/mL.

• The other ingredients (excipients) are: dimethyl sulfoxide, human serum albumin, phosphate buffered saline. See section 2 “Ebvallo contains sodium and dimethyl sulfoxide (DMSO)”.

  What Ebvallo looks like and contents of the pack

  Ebvallo is a translucent, colourless to slightly yellow cell dispersion for injection.

  Ebvallo is provided in individual patient cartons containing 1 vial to 6 vials according to the patient-specific dose required. Each vial contains 1 mL of this medicine.

  Marketing Authorisation Holder

  Pierre Fabre Limited

  250 Longwater Avenue,

  Green Park,

  Reading RG2 6GP

  United Kingdom

  Manufacturer

  PIERRE FABRE MEDICAMENT PRODUCTION

  Parc industriel de la Chartreuse

  81100 Castres

  France

  This leaflet was last revised in 09/2026

  This medicine has been authorised under ‘exceptional circumstances’. This means that because of the rarity of this disease, it has been impossible to get complete information on this medicine.

  The Medicines and Healthcare Products Regulatory Agency will review any new information on this medicine every year and this leaflet will be updated as necessary.

The following information is intended for healthcare professionals only:

It is important that you read the entire content of this procedure prior to administering Ebvallo.

Precautions to be taken before handling or administering the medicinal product

• This medicinal product contains human blood cells. Healthcare professionals handling Ebvallo must take appropriate precautions (wearing gloves and glasses) to avoid potential transmission of infectious diseases.

Preparation prior to administration

• The patient’s identity must match the patient identifiers (PFPIN and Institution Patient ID) on the accompanying Ebvallo Lot Information Sheet (LIS) and carton. Product-patient reconciliation must be performed by matching information on the LIS against 1) the carton (matching PFPIN and FDP Number) and against 2) the vial label (matching Lot Number and Donor ID). Do not prepare or administer Ebvallo if the patient’s identity or the product-patient reconciliation cannot be confirmed. Prior to thawing, ensure that the required dose calculations are completed, all materials needed to prepare the dose are available, and the patient is onsite and has been clinically evaluated.

Materials required for dose preparation

• Sterile syringes:

  • Dosing syringe (select a syringe size than can accommodate required diluent [see Prepare the diluent] and cell dispersion volume)
  • Product draw syringe (select a syringe size that can appropriately measure and will accommodate the calculated volume of cell dispersion needed)
• Diluent (sterile, non-pyrogenic multiple electrolytes solution for injection Type 1 pH 7.4)
• Aseptic devices for transferring product (18-guage unfiltered syringe needles, Luer Lock adapter, Luer Lock cap)

Dose calculations

• See the accompanying Lot Information Sheet (LIS) and

  carton for information pertaining to the concentration of cells per vial.

  • Note: The viable T-cell concentration on the LIS and carton is the actual concentration of each vial. This may be different than the nominal concentration listed on the vial label, which should not be used for dose preparation calculations. Each vial contains 1 mL deliverable volume.

Prepare the diluent

Select the appropriate diluent volume (30 mL for patient weight ≤ 40 kg; 50 mL for patient weight > 40 kg). Aseptically draw the selected volume of diluent into the dosing syringe.

Thawing

• The thawing process of Ebvallo can begin after the patient is onsite and has been clinically evaluated.
• Remove the carton from the vapour phase of liquid nitrogen at ≤ -150 °C.
• Frozen vial(s) of Ebvallo should be placed inside a sterile bag during thawing to protect from contamination and thawed upright in a 37 °C water bath or dry thawing chamber.
• Record the start of thaw time. While the medicinal product thaws, swirl the product vial(s) gently until fully thawed by inspection (approximately 2.5 to 15 minutes). Product should be removed from the thawing device immediately upon completion of thaw.
• Dose preparation must be completed within 1 hour from the start of thaw.
• Thawed or prepared product must not be refrozen. Do not irradiate.

Dilution and dose preparation

• Gently invert the vial(s) until the cell dispersion is mixed.
• Aseptically withdraw the required cell dispersion volume from the provided product vial(s) into the product draw syringe using an 18-gauge unfiltered needle.
• Aseptically transfer the cell dispersion from the product draw syringe to the dosing syringe (previously filled with diluent). Ensure entire content is transferred from the product draw syringe.

• Inspect the diluted Ebvallo in the dosing syringe: cell dispersion should appear as a translucent, hazy solution.

  If visible clumps appear, continue to gently mix the solution. Small clumps of cellular material should disperse with gentle manual mixing.

  • Maintain Ebvallo between 15 °C to 25 °C during dose preparation and administration. Dose preparation must be completed within 1 hour from the start of thaw. Administration must be completed within 3 hours from the start of thaw. Ebvallo contains 10% DMSO. Ebvallo should be administered to the patient as soon as possible after thawing.

Administration

• Administer Ebvallo as a single dose intravenously after dilution.
• It is recommended to flush the intravenous line prior to Ebvallo administration.
• Connect the final medicinal product syringe to the patient’s intravenous catheter (24-guage or larger catheter size) and inject over 5 to 10 minutes.
• Once Ebvallo is fully dispensed from the syringe, flush the intravenous line with ≥ 10 mL of sodium chloride 9 mg/mL (0.9%) solution for injection.

Measures to take in case of accidental exposure In case of accidental exposure, local guidelines on handling of human-derived material should be followed, which may include washing of the contaminated skin and removal of contaminated clothes. Work surfaces and materials which have potentially been in contact with Ebvallo must be decontaminated with appropriate disinfectant.

Precautions to be taken for the disposal of the medicinal product

Unused medicinal product and all material that has been in contact with Ebvallo (solid and liquid waste) must be handled and disposed of as potentially infectious waste in accordance with local guidelines on handling of human-derived material. XXXXXX 2.8 x 107 – 7.3 x 107 cells/mL dispersion for injection tabelecleucel

(EBV-specific viable T cells)

2.8 x 10⁷ – 7.3 x 10⁷ cells/mL dispersion for injection tabelecleucel

(EBV-specific viable T cells)

2.8 x 10₇ – 7.3 x 10₇ cells/mL dispersion for injection

tabelecleucel (EBV-specific viable T cells)

Tél. : 01 55 76 99 40 packaging@optionk.com

Client : PIERRE FABRE

Date de création : 09-12-2024

Demande de : Corinne

Produit : EBVALLO

Pays : UK.MHRA (1L) - 1 ml Format : 36x20’’ (914,4 x 508 mm) Code article : mock-up

Couleurs : noir

Texte : barlow: 9 pts - 100 %

interlignage : 10,8 pts

Epreuves : v2 : 23-01-2025

v3 : 01-09-2026 Hors estimation : v4 :

v5 :

Clôturé le :

Préalablement à toute livraison par la société OPTION K à son client de maquettes en version fichiers natifs, fichiers PDF haute définition ou tout autre type de fichier utile, la société OPTION K émet un BAT (Bon à tirer) que le client s’engage à signer. La validation du BAT par le client décharge en conséquence OPTION K de toute responsabilité.

S’agissant ensuite de toute impression définitive des maquettes qui auront été livrées par la société OPTION K à son client, ledit client s’engage à signer un bon à tirer émanant de l’imprimeur qu’il aura choisi. En l’absence de BAT/imprimeur signé par le client ou en cas de validation dudit BAT/imprimeur par lui, aucune responsabilité de la société OPTION K ne pourra être mise à charge.

VALIDATION CLIENT